MyCardium AI
MyCardium AI, a UCL spinout founded in April 2022 to transform how medical imaging is delivered in healthcare through the use of “super-human” AI. Focusing on cardiac MRI initially, our ambition is to deliver this AI to point-of-care in over 2,000 global centres. Our mission is to improve healthcare system performance, patient outcomes by delivering better diagnoses, and help create next generation treatments by analysing Cardiac Magnetic Resonance Images, using Artificial Intelligence Algorithms capable of performing the automation of heart measurement to a super-human standard.
MyCardium AI
MyCardium AI, a UCL spinout founded in April 2022 to transform how medical imaging is delivered in healthcare through the use of “super-human” AI. Focusing on cardiac MRI initially, our ambition is to deliver this AI to point-of-care in over 2,000 global centres. Our mission is to improve healthcare system performance, patient outcomes by delivering better diagnoses, and help create next generation treatments by analysing Cardiac Magnetic Resonance Images, using Artificial Intelligence Algorithms capable of performing the automation of heart measurement to a super-human standard.
TL;DR
Founded: 2022 (UCL spinout)
Headquarters: Liverpool, UK
Product focus: AI-powered cardiac imaging (cardiac MRI and echocardiography)
Regulatory / quality: FDA 510(k) clearances; CE Class IIb; ISO 13485 and ISO 27001 certifications
Team size (reported): 41 employees
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Cardiac imaging interpretation and measurement automation for clinical and research workflows.
Founded
2022
Industry
Software Development
Funding Track Record
Investor Signal
“UCL spinout with UCLB/Portico Ventures involvement; UCL retained ~4.3% equity under the Portico arrangement.”